<?xml version='1.0' encoding='utf-8'?>
<document id="28114144"><sentence text="Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective." /><sentence text="Hepatitis C virus (HCV) infection is a very common infection found among hemodialysis (HD) and kidney transplant patients" /><sentence text=" It is associated with substantial morbidity and mortality" /><sentence text=" Direct-acting antiviral agents (DAAs) have much better efficacy (sustained viral response (SVR)) and tolerance than interferon-based regimens" /><sentence text=" Very recent studies extend this breakthrough finding to chronic kidney disease (CKD) populations" /><sentence text="" /><sentence text="CKD patients with an estimated glomerular filtration rate (eGFR) &gt;30 ml/min/1" /><sentence text="73 m2 can be treated with any licensed DAA regimen" /><sentence text=" In CKD stages 4-5 (mostly HD), the combination of grazoprevir (100 mg) and elbasvir (50 mg), a once-daily oral regimen active against genotypes 1 and 4, induced in a very recent RCT an SVR rate &gt;95%, with tolerance similar to that of placebo"><entity charOffset="51-62" id="DDI-PubMed.28114144.s9.e0" text="grazoprevir" /><entity charOffset="76-84" id="DDI-PubMed.28114144.s9.e1" text="elbasvir" /><pair ddi="false" e1="DDI-PubMed.28114144.s9.e0" e2="DDI-PubMed.28114144.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28114144.s9.e0" e2="DDI-PubMed.28114144.s9.e1" /></sentence><sentence text=" Case series suggest that other DAA regimens are also very effective and well tolerated in HD patients" /><sentence text=" In kidney transplant recipients, 2 case series have reported 100% SVR with good tolerance of sofosbuvir-based regimens"><entity charOffset="94-104" id="DDI-PubMed.28114144.s11.e0" text="sofosbuvir" /></sentence><sentence text=" Importantly, there is a risk of drug-drug interaction of several DAAs including calcineurin inhibitors" /><sentence text=" Finally, the availability of HCV+ grafts may markedly shorten the waiting time for transplantation" /><sentence text=" Key Messages: (1) In patients with an eGFR &gt;30, all licensed DAAs regimens can be used" /><sentence text=" (2) Cure of HCV appears at hand in CKD stages 4-5, including dialysis patients, and in kidney transplant recipients" /><sentence text=" (3) The choice of DAA regimen in CKD should be based on HCV genotype, viral load, eGFR, concomitant medications, transplant candidacy and comorbidities" /><sentence text=" (4) The timing of treatment in potential kidney transplantation candidates (before versus after transplantation) should be decided in collaboration with the transplant center" /><sentence text=" Video Journal Club 'Cappuccino with Claudio Ronco' at http://www" /><sentence text="karger" /><sentence text="com/?doi=452730" /><sentence text="" /></document>